Oliver F. Bathe
University of Calgary
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Oliver F. Bathe.
British Journal of Surgery | 2006
Andrew McKay; S. Mackenzie; Francis Sutherland; Oliver F. Bathe; Christopher Doig; J. Dort; Charles M. Vollmer; Elijah Dixon
Pancreaticoduodenectomy is the primary treatment for periampullary cancer. Associated morbidity is high and often related to pancreatic anastomotic failure. This paper compares rates of pancreatic fistula, morbidity and mortality after pancreaticoduodenectomy in patients having reconstruction by pancreaticogastrostomy with those in patients having reconstruction by pancreaticojejunostomy.
Journal of Clinical Oncology | 2011
Richard D. Kennedy; Max Bylesjo; Peter Kerr; Timothy Davison; Julie Black; Elaine Kay; Robert J. Holt; Vitali Proutski; Miika Ahdesmäki; Vadim Farztdinov; Nicolas Goffard; Peter Hey; Fionnuala McDyer; Karl Mulligan; Julie Mussen; Eamonn J. O'Brien; Gavin R. Oliver; Steven M. Walker; Jude M. Mulligan; Claire Wilson; Andreas Winter; D O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan; Kieran Sheahan; John Hyland; Rajiv Dhir; Oliver F. Bathe; Ola Winqvist; Upender Manne
PURPOSE Current prognostic factors are poor at identifying patients at risk of disease recurrence after surgery for stage II colon cancer. Here we describe a DNA microarray-based prognostic assay using clinically relevant formalin-fixed paraffin-embedded (FFPE) samples. PATIENTS AND METHODS A gene signature was developed from a balanced set of 73 patients with recurrent disease (high risk) and 142 patients with no recurrence (low risk) within 5 years of surgery. RESULTS The 634-probe set signature identified high-risk patients with a hazard ratio (HR) of 2.62 (P < .001) during cross validation of the training set. In an independent validation set of 144 samples, the signature identified high-risk patients with an HR of 2.53 (P < .001) for recurrence and an HR of 2.21 (P = .0084) for cancer-related death. Additionally, the signature was shown to perform independently from known prognostic factors (P < .001). CONCLUSION This gene signature represents a novel prognostic biomarker for patients with stage II colon cancer that can be applied to FFPE tumor samples.
Cancer Epidemiology, Biomarkers & Prevention | 2011
Oliver F. Bathe; Rustem Shaykhutdinov; Karen Kopciuk; Aalim M. Weljie; Andrew McKay; Francis Sutherland; Elijah Dixon; Nicole Dunse; Dina Sotiropoulos; Hans J. Vogel
Background: We postulated that the abundance of various metabolites in blood would facilitate the diagnosis of pancreatic and biliary lesions, which could potentially prevent unnecessary surgery. Methods: Serum samples from patients with benign hepatobiliary disease (n = 43) and from patients with pancreatic cancer (n = 56) were examined by 1H NMR spectroscopy to quantify 58 unique metabolites. Data were analyzed by “targeted profiling” followed by supervised pattern recognition and orthogonal partial least-squares discriminant analysis (O-PLS-DA) of the most significant metabolites, which enables comparison of the whole sample spectrum between groups. Results: The metabolomic profile of patients with pancreatic cancer was significantly different from that of patients with benign disease (AUROC, area under the ROC curve, = 0.8372). Overt diabetes mellitus (DM) was identified as a possible confounding factor in the pancreatic cancer group. Thus, diabetics were excluded from further analysis. In this more homogeneous pancreatic cancer group, compared with benign cases, serum concentrations of glutamate and glucose were most elevated on multivariate analysis. In benign cases, creatine and glutamine were most abundant. To examine the usefulness of this test, a comparison was made to age- and gender-matched controls with benign lesions that mimic cancer, controlling also for presence of jaundice and diabetes (n = 14 per group). The metabolic profile in patients with pancreatic cancer remained distinguishable from patients with benign pancreatic lesions (AUROC = 0.8308). Conclusions: The serum metabolomic profile may be useful for distinguishing benign from malignant pancreatic lesions. Impact: Further studies will be required to study the effects of jaundice and diabetes. A more comprehensive metabolomic profile will be evaluated using mass spectrometry. Cancer Epidemiol Biomarkers Prev; 20(1); 140–7. ©2010 AACR.
Journal of Immunology | 2004
Roberto Carrio; Oliver F. Bathe; Thomas R. Malek
Although much is known concerning the immunobiology of CD8+ T memory cells, the initial events favoring the generation of CD8+ T memory cells remain poorly defined. Using a culture system that yields memory-like CD8+ T cells, we show that 1 day after Ag encounter, Ag-activated T cells developed into memory-like T cells, but this optimally occurred 3 days after Ag encounter. Key phenotypic, functional, and molecular properties that typify central memory T cells were expressed within 48 h when the activated CD8+ T cells were cultured with IL-7 or IL-15 in the absence of Ag or following transfer into normal mice. These data support a model whereby Ag activation of naive CD8+ T cells not only programs effector cell expansion and contraction but the potential to develop into a memory cell which ensues in an Ag-free environment containing IL-7 or IL-15.
Genome Medicine | 2012
Farshad Farshidfar; Aalim M. Weljie; Karen Kopciuk; W Don Buie; Anthony R. MacLean; Elijah Dixon; Francis Sutherland; Andrea Molckovsky; Hans J. Vogel; Oliver F. Bathe
BackgroundPresently, colorectal cancer (CRC) is staged preoperatively by radiographic tests, and postoperatively by pathological evaluation of available surgical specimens. However, present staging methods do not accurately identify occult metastases. This has a direct effect on clinical management. Early identification of metastases isolated to the liver may enable surgical resection, whereas more disseminated disease may be best treated with palliative chemotherapy.MethodsSera from 103 patients with colorectal adenocarcinoma treated at the same tertiary cancer center were analyzed by proton nuclear magnetic resonance (1H NMR) spectroscopy and gas chromatography-mass spectroscopy (GC-MS). Metabolic profiling was done using both supervised pattern recognition and orthogonal partial least squares-discriminant analysis (O-PLS-DA) of the most significant metabolites, which enables comparison of the whole sample spectrum between groups. The metabolomic profiles generated from each platform were compared between the following groups: locoregional CRC (N = 42); liver-only metastases (N = 45); and extrahepatic metastases (N = 25).ResultsThe serum metabolomic profile associated with locoregional CRC was distinct from that associated with liver-only metastases, based on 1H NMR spectroscopy (P = 5.10 × 10-7) and GC-MS (P = 1.79 × 10-7). Similarly, the serum metabolomic profile differed significantly between patients with liver-only metastases and with extrahepatic metastases. The change in metabolomic profile was most markedly demonstrated on GC-MS (P = 4.75 × 10-5).ConclusionsIn CRC, the serum metabolomic profile changes markedly with metastasis, and site of disease also appears to affect the pattern of circulating metabolites. This novel observation may have clinical utility in enhancing staging accuracy and selecting patients for surgical or medical management. Additional studies are required to determine the sensitivity of this approach to detect subtle or occult metastatic disease.
Journal of Surgical Oncology | 2011
Vanessa Wylie Davis; Oliver F. Bathe; Daniel Schiller; Carolyn M. Slupsky; Michael B. Sawyer
Metabolomics, the newest of the “omics” sciences, has brought much excitement to the field of oncology as a potential new translational tool capable of bringing the molecular world of cancer care to the bedside. While still early in its development, metabolomics could alter the scope and role of surgery in the multidisciplinary treatment of cancer. This review examines potential roles of metabolomics in areas of early cancer detection, personalized therapeutics and tumorigenesis. J. Surg. Oncol. 2011; 103:451–459.
Cell Reports | 2017
Farshad Farshidfar; Siyuan Zheng; Marie-Claude Gingras; Yulia Newton; Juliann Shih; A. Gordon Robertson; Toshinori Hinoue; Katherine A. Hoadley; Ewan A. Gibb; Jason Roszik; Kyle Covington; Chia Chin Wu; Eve Shinbrot; Nicolas Stransky; Apurva M. Hegde; Ju Dong Yang; Ed Reznik; Sara Sadeghi; Chandra Sekhar Pedamallu; Akinyemi I. Ojesina; Julian Hess; J. Todd Auman; Suhn Kyong Rhie; Reanne Bowlby; Mitesh J. Borad; Andrew X. Zhu; Josh Stuart; Chris Sander; Rehan Akbani; Andrew D. Cherniack
Summary Cholangiocarcinoma (CCA) is an aggressive malignancy of the bile ducts, with poor prognosis and limited treatment options. Here, we describe the integrated analysis of somatic mutations, RNA expression, copy number, and DNA methylation by The Cancer Genome Atlas of a set of predominantly intrahepatic CCA cases and propose a molecular classification scheme. We identified an IDH mutant-enriched subtype with distinct molecular features including low expression of chromatin modifiers, elevated expression of mitochondrial genes, and increased mitochondrial DNA copy number. Leveraging the multi-platform data, we observed that ARID1A exhibited DNA hypermethylation and decreased expression in the IDH mutant subtype. More broadly, we found that IDH mutations are associated with an expanded histological spectrum of liver tumors with molecular features that stratify with CCA. Our studies reveal insights into the molecular pathogenesis and heterogeneity of cholangiocarcinoma and provide classification information of potential therapeutic significance.
Annals of Surgery | 2004
Lloyd A. Mack; Ioannis Kaklamanos; Alan S. Livingstone; Joe U. Levi; Carolyn Robinson; Danny Sleeman; Dido Franceschi; Oliver F. Bathe
Objective:The objective of this study was to assess the feasibility and safety of inserting a double-lumen gastrojejunostomy tube (GJT) after pancreaticoduodenectomy (PD) and to evaluate associated outcomes. Background:Gastroparesis is a frequent postoperative event following PD. This often necessitates prolonged gastric decompression and nutritional support. A double-lumen GJT may be particularly useful in this situation: gastric decompression may be achieved through the gastric port without a nasogastric tube; enteral feeding may be administered through the jejunal port. Methods:Thirty-six patients with periampullary tumors were randomized at the time of PD to insertion of GJT or to the routine care of the operating surgeon. Outcomes, including length of stay, complications, and costs, were followed prospectively. Results:The 2 groups had similar characteristics. Prolonged gastroparesis occurred in 4 controls (25%) and in none of the patients who had a GJT (P = 0.03). Complication rates were similar in each group. Mean postoperative length of stay was significantly longer in controls compared with patients who had a GJT (15.8 ± 7.8 days versus 11.5 ± 2.9 days, respectively; P = 0.01). Hospital charges were
Genetics in Medicine | 2009
Oliver F. Bathe; Amy L. McGuire
82,151 ± 56,632 in controls and
Cancer | 2008
Jennica K.S. Ng; Stefan J. Urbanski; Naurang Mangat; Andrew McKay; Francis Sutherland; Elijah Dixon; Scot Dowden; Scott Ernst; Oliver F. Bathe
52,589 ± 15,964 in the GJT group (P = 0.036). Conclusions:In patients undergoing PD, insertion of a GJT is safe. Moreover, insertion of a GJT improves average length of stay. At the time of resection of periampullary tumors, GJT insertion should be considered, especially given this is a patient population in which weight loss and cachexia are frequent.